BioSpace News Archive

Biotech Bay

Pear Therapeutics to Present at the Citi 15th Annual BioPharma Virtual Conference

Pear Therapeutics, Inc. today announced that Corey McCann, M.D., Ph.D., President and CEO, will present at the Citi 15th Annual BioPharma Virtual Conference on Tuesday, September 8 at 10:40 a.m. Eastern Time.

September 1, 2020
·
1 min read
BioCapital

Local Coverage Determinations for Implantable CGMs Announced by Three Medicare Administrative Contractors

Senseonics Holdings, Inc. announced that three Medicare Administrative Contractors have issued Local Coverage Determinations for the use of implantable CGM systems, such as the Eversense® CGM System.

September 1, 2020
·
3 min read
BioCapital

Immunomic Therapeutics Announces Publication of Results from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Treatment of GBM

Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that results from multiple ATTAC clinical studies of dendritic cell vaccines have been published online by American Associatio

September 1, 2020
·
6 min read
Biotech Beach

Advantu Medtech and Biotech Software Engineering Expands Partner Program

Advantu Inc, the most sought after Biotech and Medical Device software engineering team, is proud to announce they are expanding their partner program to the Midwest and the Southeast.

September 1, 2020
·
2 min read
Biotech Bay

Align Technology Extends Innovation With New Invisalign Stickables – Designed To Personalize Invisalign® Clear AlignersPatent-pending sticker accessories make each Invisalign aligner as unique as the patient wearing them

Align Technology, Inc. announced the launch of Invisalign® Stickables, innovative sticker accessories designed exclusively for use with the patented SmartTrack® material in Invisalign clear aligners.

September 1, 2020
·
3 min read
Business

Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, to exclusively license its JTX-1811 program.

September 1, 2020
·
6 min read
Business

Jonathan DeCarlo Named Chief Financial Officer at Emmes

Emmes announced that Jonathan DeCarlo has been promoted to chief financial officer.

September 1, 2020
·
2 min read
Pharm Country

NCCN Oncology Research Program, with Taiho Oncology, to Explore New Research into Oral Medication Targeting Tumor Suppression Genes

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced plans to develop a program to scientifically evaluate and facilitate clinical trials on the efficacy of decitabine and cedazuridine

September 1, 2020
·
3 min read
Starpharma creates slow release soluble DEP remdesivir nanoparticle

Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has applied its novel DEP® drug delivery technology to create a long‑acting, water soluble version of remdesivir.

September 1, 2020
·
4 min read
Drug Development

INmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor™ in a Blinded Randomized Phase 2 Trial for Immune Mediated Complications in COVID-19 Patients

INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating Quellor™

September 1, 2020
·
5 min read